THE BRAND NEW York Times: Amgen LIKELY TO Plead Guilty In U.S. Case But one individual near to the investigation said Amgen would plead guilty to misbranding, a charge that always refers to promoting medications for uses not approved by the meals and Drug Administration. Amgen announced 14 weeks ago that it had reserve $780 million for a settlement of federal and state investigations and 10 distinct whistle-blower lawsuits. A lot of the investigations are thought to involve its anemia drugs, Epogen and Aranesp.In physiology and biophysics from the University of California at Irvine in 1994. He did post-doctoral work at the University of Texas Southwestern Medical Center in Dallas. Technology is released by the American Association for the Advancement of Technology, an international nonprofit organization with a mission to ‘advance science and serve culture’ through initiatives in technology policy, international programs, research education and the publication of scientific news letters, books and reports.